Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2012British Journal of HaematologyOpen Access

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

GCGaetano CorazzelliFAF. AngrilliADAlfonso Maria D’Arco

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Corazzelli et al. (2012) studied this question.

synapsesocial.com/papers/6a70f9596ceb2bbd16e009eehttps://doi.org/10.1111/bjh.12120
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment2011 · 373 citations
  2. 2Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines1996 · 155 citations
  3. 3BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients2011 · 139 citations
  4. 4State-of-the-Art Therapeutics: Hodgkin's Lymphoma2005 · 237 citations